1 active not recruiting, 1 completed, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
Follow TCR2 Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer TC-510, Fludarabine, Cyclophosphamide - Mesothelioma, Mesotheliomas Pleural | Phase 1 / Phase 2 | Terminated | TCR2 Therapeutics | 14 | 2022-06-21 | 2026-07-13 |
| TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia TC-110 T Cells, Fludarabine, Cyclophosphamide - Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | TCR2 Therapeutics | 6 | 2020-03-27 | 2023-03-16 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer gavo-cel, fludarabine, cyclophosphamide - Mesothelioma, Mesothelioma, Malignant | Phase 1 / Phase 2 | Active not recruiting | TCR2 Therapeutics | 57 | 2019-04-15 | 2025-08-27 |
Carcinoma, Non-Small-Cell Lung (2) · Cholangiocarcinoma (2) · Mesothelioma (2) · Mesothelioma, Malignant (2) · Ovarian Neoplasms (2) · Colorectal Neoplasms (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Pancreatic Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Triple Negative Breast Neoplasms (1)
Cyclophosphamide (3) · fludarabine (3) · Ipilimumab (1) · Nivolumab (1)
United States (3) · Canada (1)